With the share price of Braveheart Investment Group surging by around 100 percent in the space of a week, the investment firm has issued a share price movement statement that reminded investors of an upcoming milestone.
The upcoming milestone is that of test data related to its investment in a COVID-19 test that Paraytec Limited is working on in partnership with the University of Sheffield.
Explaining the soaring share price, Braveheart noted that clinical testing results were due at the end of this month:
“In the update it was noted that the pipeline of clinical samples was now fully operational and additional staff had been recruited to process samples for performance assessment. The update also stated that the results from this phase of clinical testing were expected by the end of February and this remains the case. Until the results of the testing are known there can be no certainty that the tests will be successful.”
The share price of Braveheart is currently trading at 88p; having touched 100p shortly following today’s RNS.